Teva nasal allergy spray approved; Topical formulation of ibuprofen under development;

> The FDA approved Teva's ($TEVA) QNASL for the treatment of nasal symptoms of allergic rhinitis. The company says it is the first nasal allergy spray approved for children as young as four years old. It is a lower dose formulation of the medication meant for adults. Release

> Strategic Science and Technologies (SST) signed an agreement that gives an unnamed, large over-the-counter healthcare company an exclusive option to the obtain U.S. commercial rights to SST's topical formulation of ibuprofen once it gets approved by the FDA. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.